Compare AbCellera Biologics Inc (ABCL) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

XLK trades at $183.60, up 1.73% with a neutral technical signal. The ETF has gained 33% year-to-date, making it the top-performing sector SPDR in 2026. Recent news highlights strong tech sector inflows and investor rotation patterns. Technical indicators show mixed signals with RSI readings in neutral territory and key support at $182.

Outlook remains positive given strong sector performance, though risks include potential Fed policy shifts and tech sector volatility. The ETF's low expense ratio and concentrated tech exposure provide competitive advantages, but investors should monitor macroeconomic indicators that could impact tech valuations.